Pacific Biosciences of California - PACB Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $6.59
  • Forecasted Upside: 252.46%
  • Number of Analysts: 15
  • Breakdown:
  • 0 Sell Ratings
  • 7 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$1.87
▼ -0.07 (-3.61%)

This chart shows the closing price for PACB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pacific Biosciences of California Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PACB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PACB

Analyst Price Target is $6.59
▲ +252.46% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Pacific Biosciences of California in the last 3 months. The average price target is $6.59, with a high forecast of $15.00 and a low forecast of $2.00. The average price target represents a 252.46% upside from the last price of $1.87.

This chart shows the closing price for PACB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 15 polled investment analysts is to moderate buy stock in Pacific Biosciences of California. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings
12/4/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings
3/4/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings
6/2/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings
8/31/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings
11/29/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings
2/27/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings
4/27/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings
5/27/2024

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$10.00 ➝ $4.00Low
5/13/2024Piper SandlerLower TargetNeutral ➝ Neutral$6.50 ➝ $2.00Low
5/10/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$3.00 ➝ $2.00Low
4/22/2024JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
4/18/2024Sanford C. BernsteinLower TargetOutperform ➝ Outperform$9.00 ➝ $2.50Low
4/18/2024The Goldman Sachs GroupDowngradeBuy ➝ Neutral$7.00 ➝ $2.50Low
4/18/2024ScotiabankLower TargetSector Outperform ➝ Sector Outperform$15.00 ➝ $8.00Low
4/17/2024TD CowenLower TargetBuy ➝ Buy$12.00 ➝ $2.50N/A
4/10/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$8.00 ➝ $3.00Low
4/10/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$9.00 ➝ $7.00Low
2/16/2024UBS GroupLower TargetBuy ➝ Buy$12.50 ➝ $12.00Low
12/14/2023StephensInitiated CoverageOverweight$11.00Low
12/14/2023GuggenheimInitiated CoverageNeutralLow
12/13/2023Wolfe ResearchInitiated CoveragePeer PerformLow
11/17/2023UBS GroupUpgradeNeutral ➝ Buy$13.00 ➝ $10.00Low
11/6/2023Piper SandlerLower TargetNeutral ➝ Neutral$9.00 ➝ $8.00Low
10/31/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$17.00 ➝ $15.00Low
10/31/2023Cantor FitzgeraldUpgradeNeutral ➝ Overweight$14.00 ➝ $11.00Low
10/24/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$13.00 ➝ $10.00Low
10/16/2023Piper SandlerLower TargetNeutral ➝ Neutral$13.00 ➝ $9.00Low
9/29/2023BarclaysLower TargetEqual Weight ➝ Equal Weight$14.00 ➝ $9.00Low
9/28/2023Sanford C. BernsteinInitiated CoverageOutperform$11.00Low
9/26/2023Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$14.00Low
8/22/2023Cantor FitzgeraldReiterated RatingNeutral ➝ Neutral$14.00Low
8/3/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$12.00 ➝ $13.00Low
6/30/2023The Goldman Sachs GroupInitiated CoverageBuy$17.00Low
6/7/2023KGI SecuritiesInitiated CoverageOutperformLow
5/10/2023BarclaysInitiated CoverageEqual Weight$14.00Low
5/8/2023Piper SandlerBoost Target$10.00 ➝ $13.00Low
5/3/2023Cantor FitzgeraldBoost Target$12.00 ➝ $13.00Low
3/31/2023TD CowenUpgradeMarket Perform ➝ Outperform$13.00 ➝ $15.00Low
2/22/2023Piper SandlerLower Target$11.00 ➝ $10.00Low
2/2/2023UBS GroupInitiated CoverageNeutral$13.00Low
1/20/2023Cantor FitzgeraldDowngradeOverweight ➝ Neutral$12.00Low
1/4/2023ScotiabankInitiated CoverageSector Outperform$12.00Low
11/16/2022Canaccord Genuity GroupBoost Target$12.00 ➝ $14.00Low
11/16/2022Piper SandlerBoost Target$6.00 ➝ $11.00Low
8/21/2022Piper SandlerLower Target$7.50 ➝ $6.00Low
8/17/2022Piper SandlerBoost TargetNeutral$6.00 ➝ $7.50Low
8/9/2022CowenLower Target$8.00Low
8/5/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$17.00 ➝ $14.00Low
7/19/2022CowenSet Target$9.00Low
5/15/2022Piper SandlerLower TargetNA$13.00 ➝ $6.00High
5/5/2022Cantor FitzgeraldLower Target$23.00 ➝ $19.00High
3/1/2022Piper SandlerLower Target$20.00 ➝ $13.00High
2/16/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$45.00 ➝ $40.00High
1/25/2022Cantor FitzgeraldReiterated RatingOverweightHigh
8/4/2021Morgan StanleyLower TargetEqual Weight$45.00 ➝ $41.00High
7/9/2021Cantor FitzgeraldReiterated RatingOverweightHigh
2/12/2021Morgan StanleyBoost TargetEqual Weight$12.00 ➝ $45.00Low
2/11/2021Cantor FitzgeraldBoost TargetIn-Line ➝ Overweight$45.00 ➝ $62.00Low
2/11/2021Piper SandlerUpgradeNeutral ➝ Overweight$20.00 ➝ $52.00Low
1/15/2021Piper SandlerBoost TargetNeutral$12.00 ➝ $20.00Medium
1/12/2021Cantor FitzgeraldBoost TargetReduce ➝ Overweight$25.00 ➝ $45.00Medium
12/8/2020Cantor FitzgeraldBoost TargetOverweight$16.00 ➝ $25.00Low
11/4/2020Morgan StanleyBoost TargetEqual Weight$7.00 ➝ $12.00High
11/3/2020Piper SandlerDowngradeOverweight ➝ Neutral$12.00High
10/13/2020Cantor FitzgeraldBoost TargetOverweight$11.00 ➝ $17.00High
10/2/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$15.00Low
10/1/2020Piper SandlerBoost TargetOverweight$6.00 ➝ $12.00High
9/9/2020Morgan StanleyInitiated CoverageEqual Weight$7.00Low
6/10/2020Cantor FitzgeraldReiterated RatingBuy$5.00High
6/1/2020Cantor FitzgeraldInitiated CoverageBuy$5.00High
5/7/2020Piper SandlerLower TargetOverweight$7.00 ➝ $6.00Medium
4/17/2020Cantor FitzgeraldReiterated RatingOverweightMedium
3/9/2020Cantor FitzgeraldReiterated RatingOverweight$5.00Medium
12/18/2019Piper Sandler CompaniesReiterated RatingBuy$7.00Low
10/15/2019Piper Sandler CompaniesUpgradeNeutral ➝ Overweight$8.00High
6/20/2019Cantor FitzgeraldSet TargetHold$8.00Low
6/13/2019Cantor FitzgeraldReiterated RatingHoldLow
(Data available from 5/28/2019 forward)

News Sentiment Rating

0.48 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/31/2023
  • 6 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/30/2023
  • 4 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/30/2023
  • 7 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/29/2024
  • 16 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
2/28/2024
  • 9 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
3/29/2024
  • 4 very positive mentions
  • 13 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
4/28/2024
  • 9 very positive mentions
  • 17 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
5/28/2024

Current Sentiment

  • 9 very positive mentions
  • 17 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Pacific Biosciences of California logo
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $1.87
Low: $1.86
High: $2.03

50 Day Range

MA: $2.45
Low: $1.36
High: $3.84

52 Week Range

Now: $1.87
Low: $1.25
High: $14.55

Volume

8,742,300 shs

Average Volume

12,005,746 shs

Market Capitalization

$509.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.99

Frequently Asked Questions

What sell-side analysts currently cover shares of Pacific Biosciences of California?

The following sell-side analysts have issued stock ratings on Pacific Biosciences of California in the last year: Barclays PLC, Canaccord Genuity Group Inc., Cantor Fitzgerald, Guggenheim, JPMorgan Chase & Co., KGI Securities, Morgan Stanley, Piper Sandler, Sanford C. Bernstein, Scotiabank, Stephens, StockNews.com, TD Cowen, The Goldman Sachs Group, Inc., UBS Group AG, and Wolfe Research.
View the latest analyst ratings for PACB.

What is the current price target for Pacific Biosciences of California?

11 Wall Street analysts have set twelve-month price targets for Pacific Biosciences of California in the last year. Their average twelve-month price target is $6.59, suggesting a possible upside of 252.5%. Canaccord Genuity Group Inc. has the highest price target set, predicting PACB will reach $15.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $2.00 for Pacific Biosciences of California in the next year.
View the latest price targets for PACB.

What is the current consensus analyst rating for Pacific Biosciences of California?

Pacific Biosciences of California currently has 7 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for PACB.

What other companies compete with Pacific Biosciences of California?

How do I contact Pacific Biosciences of California's investor relations team?

Pacific Biosciences of California's physical mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company's listed phone number is (650) 521-8000 and its investor relations email address is [email protected]. The official website for Pacific Biosciences of California is www.pacb.com. Learn More about contacing Pacific Biosciences of California investor relations.